McGill University
mcgill.caMatched: McGill University Health Centre/Research Institute of the McGill University Health Centre · McGill University
Live pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
656
Active
137
Phase 3
49
Total enrollment
204,493
Pipeline matrix
Showing 40 of 48 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| acetaminophen | — | — | — | — | 2 | ||
| B/F/TAF | — | — | — | — | — | 1 | |
| Dabigatran | — | — | — | — | — | 1 | |
| Apixaban | — | — | — | — | — | 1 | |
| edoxaban | — | — | — | — | — | 1 | |
| Rivaroxaban | — | — | — | — | — | 1 | |
| Clindamycin + primaquine | — | — | — | — | — | 1 | |
| Pentamidine | — | — | — | — | — | 1 | |
| Atovaquone | — | — | — | — | — | 1 | |
| Systemic corticosteroids | — | — | — | — | — | 1 | |
| Ustekinumab 90 mg SC q8w | — | — | — | — | — | 1 | |
| Ustekinumab 90 mg SC q12w | — | — | — | — | — | 1 | |
| Empagliflozin | — | — | — | — | — | 1 | |
| Normal saline | — | — | — | 4 | |||
| Dexamethasone | — | — | — | — | 2 | ||
| Rifampin double dose | — | — | — | — | 2 | ||
| Vancomycin | — | — | — | — | — | 2 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Fidaxomicin | — | — | — | — | — | 1 | |
| Semaglutide with 4 meal strategies | — | — | — | — | — | 1 | |
| Intervention Period 1: Semaglutide + Empagliflozin | — | — | — | — | — | 1 | |
| Intervention Period 2: Semaglutide + Empagliflozin Placebo | — | — | — | — | — | 1 | |
| Intervention Period 3: Semaglutide Placebo + Empagliflozin | — | — | — | — | — | 1 | |
| Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo | — | — | — | — | — | 1 | |
| Oral Vancomycin Prophylaxis | — | — | — | — | — | 1 | |
| rifampin standard arm | — | — | — | — | — | 1 | |
| levofloxacin and rifapentine | — | — | — | — | — | 1 | |
| FLOT | — | — | — | — | — | 2 | |
| Simvastatin | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Canagliflozin 300Mg Tab | — | — | — | — | — | 1 | |
| Inactivated influenza vaccine (IIV) at baseline | — | — | — | — | — | 1 | |
| COVID-19 Vaccines at a 3-month interval | — | — | — | — | — | 1 | |
| Inactivated influenza vaccine at Month 1 | — | — | — | — | — | 1 | |
| COVID-19 Vaccines at a 6-month interval | — | — | — | — | — | 1 | |
| Canagliflozin 300 MG | — | — | — | — | — | 1 | |
| Eligard | — | — | — | — | — | 1 | |
| Metformin | — | — | — | 3 | |||
| Sildenafil Citrate | — | — | — | — | — | 1 | |
| Standard dose rifampicin | — | — | — | — | — | 1 |
8 more active programs hidden
Next readouts
- 2021-10-20
- 2021-12-31
- 2025-05
- 2026-06-01
- 2026-07
- 2026-10-31
- 2026-12-15
- 2027-01
- 2027-01
- 2027-01-01
Top conditions
- Stroke15
- Type 1 Diabetes14
- Diabetes Mellitus, Type 113
- Healthy10
- HIV Infections8
- Chronic Obstructive Pulmonary Disease8
- HIV7
- COPD7
Frequently asked questions about McGill University
- How many clinical trials does McGill University have on ClinicalTrials.gov?
- McGill University is listed as the lead sponsor on 656 clinical trials in ClinicalTrials.gov, 137 of which are currently active (recruiting, enrolling, or ongoing).
- How many of McGill University's trials are in Phase 3?
- 49 of McGill University's trials are in Phase 3, spread across 48 active drug programs.
- What therapeutic areas does McGill University focus on?
- McGill University's most-studied conditions on ClinicalTrials.gov are Stroke, Type 1 Diabetes, Diabetes Mellitus, Type 1, Healthy, HIV Infections.
- When are McGill University's next clinical trial readouts?
- McGill University has 10 upcoming primary-completion readouts tracked here; the soonest is “Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM”, expected around 2021-10-20.